Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "AVOID"ing harm by a double-edged sword: is there a role for ultrafiltration in heart failure?1 passage
• "Biomarking" the transition from genetic risk to kidney disease.1 passage
• "Dysmorphic" lysosomes in proximal tubular cells are not specific for CINAC/CKDu and do not provide evidence that CINAC/CKDu is a toxin-induced disease.1 passage
• "In my beginning is my end": usefulness of repeat kidney biopsies in lupus nephritis.1 passage
• "Permissive AKI" with treatment of heart failure.1 passage
• "To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease.1 passage
• 'How long have I got doctor?' The development and validation of a new prognostic model.1 passage
• A CRISP(e)R view on kidney organoids allows generation of an induced pluripotent stem cell-derived kidney model for drug discovery.1 passage
• A Kidney International "journal of the COVID-19 year" in kidney transplantation.1 passage
• A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney disease.1 passage
• A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.1 passage
• A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists.1 passage
• A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure.1 passage
• A case-control study indicates that coagulation imbalance is associated with arteriosclerosis and markers of endothelial dysfunction in kidney failure.1 passage
• A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.1 passage
• A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.1 passage
• A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts.1 passage
• A collagen-binding protein enables molecular imaging of kidney fibrosis in vivo.1 passage
• A coming of age for vascular access research: the good, the bad, and the ugly!1 passage
• A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.1 passage
• A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.1 passage
• A composite score associated with spontaneous operational tolerance in kidney transplant recipients.1 passage
• A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy.1 passage
• A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout.1 passage
• A dearth of data: the problem of phosphorus in prescription medications.1 passage
• A distinct bone phenotype in ADPKD patients with end-stage renal disease.1 passage
• A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis.1 passage
• A grain of salt on kidney dendritic cell function in allograft rejection.1 passage
• A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases.1 passage
• A label-free approach by infrared spectroscopic imaging for interrogating the biochemistry of diabetic nephropathy progression.1 passage
• A metabolite-GWAS (mGWAS) approach to unveil chronic kidney disease progression.1 passage
• A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease.1 passage
• A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.1 passage
• A more direct way to measure glomerular albumin permeability-even in human glomeruli!1 passage
• A mouse model of pseudohypoaldosteronism type II reveals a novel mechanism of renal tubular acidosis.1 passage
• A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19).1 passage
• A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.1 passage
• A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas1 passage
• A multicenter cohort study of potential living kidney donors provides predictors of living kidney donation and non-donation.1 passage
• A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function.1 passage
• A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit for arteriovenous fistulas.1 passage
• A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.1 passage
• A multicenter study to develop a non-invasive radiomic model to identify urinary infection stone in vivo using machine-learning.1 passage
• A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.1 passage
• A multiple 24-hour urine collection study indicates that kidney function decline is related to urinary sodium and potassium excretion in patients with chronic kidney disease.1 passage
• A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis.1 passage
• A mutation in transcription factor MAFB causes Focal Segmental Glomerulosclerosis with Duane Retraction Syndrome.1 passage
• A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan.1 passage
• A nationwide evaluation of deceased donor kidney transplantation indicates detrimental consequences of early graft loss.1 passage
• A new BEACON of hope for the treatment of inflammation? The endogenous metabolite itaconate as an alternative activator of the KEAP1-Nrf2 system.1 passage
• A new CTGF target in renal fibrosis.1 passage
• A new epitope-tagged Pkhd1 allele sheds light on fibrocystin signaling.1 passage
• A new mouse model of anti-GBM disease sheds light on maternal transfer of alloantibodies in glomerular disease.1 passage
• A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.1 passage
• A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli.1 passage
• A novel claudin-10 mutation with a unique mechanism in two unrelated families with HELIX syndrome.1 passage
• A novel model of autosomal recessive polycystic kidney questions the role of the fibrocystin C-terminus in disease mechanism.1 passage
• A novel model of nephrotic syndrome results from a point mutation in Lama5 and is modified by genetic background.1 passage
• A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.1 passage
• A novel role for renal epithelial cells and the medullary sodium gradient in the local immune response.1 passage
• A novel role of renin inhibitor in the complement cascade.1 passage
• A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis.1 passage
• A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.1 passage
• A polycystin-centric view of cyst formation and disease: the polycystins revisited.1 passage
• A population-based approach to assess the heritability and distribution of renal handling of electrolytes.1 passage
• A population-based cohort study defines prognoses in severe chronic kidney disease.1 passage
• A practical guide to multiple imputation of missing data in nephrology.1 passage
• A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.1 passage
• A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.1 passage
• A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.1 passage
• A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.1 passage
• A propensity score-matched analysis indicates screening for asymptomatic coronary artery disease does not predict cardiac events in kidney transplant recipients.1 passage
• A proposal for standardized grading of chronic changes in native kidney biopsy specimens.1 passage
• A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death.1 passage
• A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years.1 passage
• A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children.1 passage
• A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.1 passage
• A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.1 passage
• A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent.1 passage
• A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome.1 passage
• A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health.1 passage
• A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.1 passage
• A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass.1 passage
• A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk.1 passage
• A randomized trial of intravenous and oral iron in chronic kidney disease.1 passage
• A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.1 passage
• A rational approach to the use of sophisticated genetic analyses of pediatric stone disease.1 passage
• A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.1 passage
• A reciprocal regulation of spermidine and autophagy in podocytes maintains the filtration barrier.1 passage
• A remedy for kidney disease successfully alters the cold shock protein response during inflammation.1 passage
• A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.1 passage
• A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3.1 passage
• A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.1 passage
• A rose by any other name: is stage 3a chronic kidney disease really a disease?1 passage
• A scoring system to screen elderly potential kidney transplant recipients: a simple tool for a complex task.1 passage
• A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.1 passage
• A simple clinical tool to inform the decision-making process to refer elderly incident dialysis patients for kidney transplant evaluation.1 passage
• A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.1 passage
• A single weekly Kt/Vurea target for peritoneal dialysis patients does not provide an equal dialysis dose for all.1 passage
• A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.1 passage
• A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.1 passage
• A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury.1 passage
• A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.1 passage
• A systematic review and meta-analysis indicates long-term risk of chronic and end-stage kidney disease after preeclampsia.1 passage
• A systematic review and meta-analysis indicates underreporting of renal dysfunction following endovascular aneurysm repair.1 passage
• A systematic review and meta-analysis of murine models of uremic cardiomyopathy.1 passage
• A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population.1 passage
• A systematic review and participant-level meta-analysis found little association of retinal microvascular caliber with reduced kidney function.1 passage
• A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection.1 passage
• A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse.1 passage
• A transgenic mouse model reproduces human hereditary systemic amyloidosis.1 passage
• ACE2 as therapy for glomerular disease: the devil is in the detail.1 passage
• AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms.1 passage
• AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis.1 passage
• ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?1 passage
• ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation.1 passage
• ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype.1 passage
• APOL1 and blood pressure changes in young adults.1 passage
• APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.1 passage
• APOL1 at 10 years: progress and next steps.1 passage
• APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults.1 passage
• APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy.1 passage
• APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.1 passage
• APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.1 passage
• APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.1 passage
• APOL1 risk variants and death among African American hemodialysis patients: survival of the fittest?1 passage
• APOL1 toxin, innate immunity, and kidney injury.1 passage
• APOL1-associated kidney disease in northern Nigerians with treated HIV infection.1 passage
• APOL1: a case in point for replacing race with genetics.1 passage
• AT2 receptor stimulation inhibits phosphate-induced vascular calcification.1 passage
• ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis.1 passage
• ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation.1 passage
• Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.1 passage
• Aberrant IgM on T cells: biomarker or pathogenic factor in childhood nephrotic syndrome?1 passage
• Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.1 passage
• Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.1 passage
• Accumulation of natriuretic peptides is associated with protein energy wasting and activation of browning in white adipose tissue in chronic kidney disease.1 passage
• Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis.1 passage
• Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.1 passage
• Activated ERK1/2 increases CD44 in glomerular parietal epithelial cells leading to matrix expansion.1 passage
• Activation of fibroblastic reticular cells in kidney lymph node during crescentic glomerulonephritis.1 passage
• Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells.1 passage
• Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?1 passage
• Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.1 passage
• Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.1 passage
• Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.1 passage
• Acute kidney injury complicating nephrotic syndrome of minimal change disease.1 passage
• Acute kidney injury due to tropical infectious diseases and animal venoms: a tale of 2 continents.1 passage
• Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment.1 passage
• Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?1 passage
• Acute kidney injury in patients hospitalized with COVID-19.1 passage
• Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19.1 passage
• Acute kidney injury is a risk factor for subsequent proteinuria.1 passage
• Acute kidney injury is associated with microvascular myocardial damage following myocardial infarction.1 passage
• Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation.1 passage
• Adaptor protein is a new therapeutic target in chronic kidney disease.1 passage
• Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.1 passage
• Adjusting cardiopulmonary bypass flow or arterial pressure to maintain renal medullary oxygen.1 passage
• Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.1 passage
• Advanced glycation end products in the pathogenesis of chronic kidney disease.1 passage
• After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.1 passage
• Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.1 passage
• Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis.1 passage
• Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes.1 passage
• Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.1 passage
• Alcohol consumption is inversely associated with the risk of developing chronic kidney disease.1 passage
• Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.1 passage
• Aliskiren inhibits renin-mediated complement activation.1 passage
• Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis.1 passage
• Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.1 passage
• Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.1 passage
• Alternatively spliced isoforms of WT1 control podocyte-specific gene expression.1 passage
• Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.1 passage
• Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease.1 passage
• An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.1 passage
• An alternative hypothesis to the widely held view that renal excretion of sodium accounts for resistance to salt-induced hypertension.1 passage
• An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model.1 passage
• An autopsy study suggests that diabetic nephropathy is underdiagnosed.1 passage
• An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.1 passage
• An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.1 passage
• An instrumental variable approach confirms that the duration of pretransplant dialysis has a negative impact on the survival of kidney transplant recipients and quantifies the risk.1 passage
• An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis.1 passage
• An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes.1 passage
• An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.1 passage
• An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.1 passage
• An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).1 passage
• An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.1 passage
• An overview of renal metabolomics.1 passage
• An unexpected role of steroid on podocytes: from zebrafish to human nephrotic syndrome?1 passage
• Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015.1 passage
• Analysis from the EMPA-REG OUTCOME1 passage
• Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival.1 passage
• Analysis of dendritic cells and ischemia-reperfusion changes in postimplantation renal allograft biopsies may serve as predictors of subsequent rejection episodes.1 passage
• Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.1 passage
• Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli.1 passage
• Angiopoietin-like protein 2 increases renal fibrosis by accelerating transforming growth factor-β signaling in chronic kidney disease.1 passage
• Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.1 passage
• Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?1 passage
• Anks3 interacts with nephronophthisis proteins and is required for normal renal development.1 passage
• Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.1 passage
• Antagonism of profibrotic microRNA-21 improves outcome of murine chronic renal allograft dysfunction.1 passage
• Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.1 passage
• Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.1 passage
• Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report.1 passage
• Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine.1 passage
• Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.1 passage
• Anticoagulation, atrial fibrillation, and chronic kidney disease-whose side are you on?1 passage
• Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.1 passage
• Antigens, antibodies, and membranous nephropathy: a decade of progress.1 passage
• Antineutrophil cytoplasm antibody positivity, kidney impairment, and cholesterol embolization.1 passage
• Antiphospholipid syndrome and kidney disease.1 passage
• Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury.1 passage
• Apolipoprotein E-related glomerular disorders.1 passage
• Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.1 passage
• Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.1 passage
• Apolipoprotein L1: from obscurity to consistency to controversy.1 passage
• Apolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria.1 passage
• Application of new acute kidney injury biomarkers in human randomized controlled trials.1 passage
• Applications of the CRISPR-Cas9 system in kidney research.1 passage
• Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.1 passage
• Are Pax proteins potential therapeutic targets in kidney disease and cancer?1 passage
• Are sensitized patients better off with a desensitization transplant or waiting on dialysis?1 passage
• Are women more susceptible to renal dysfunction than men?1 passage
• Arrhythmia in hemodialysis patients and its relation to sudden death.1 passage
• Arterial "inflammaging" drives vascular calcification in children on dialysis.1 passage
• Arterial oxygen content regulates plasma erythropoietin independent of arterial oxygen tension: a blinded crossover study.1 passage
• Artificial intelligence for optimal anemia management in end-stage renal disease.1 passage
• Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease.1 passage
• Assessing the risk of incident hypertension and chronic kidney disease after exposure to shock wave lithotripsy and ureteroscopy.1 passage
• Association between hepatitis C virus and chronic kidney disease: heterogeneity begets heterogeneity.1 passage
• Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.1 passage
• Association of oliguria with the development of acute kidney injury in the critically ill.1 passage
• Association of short sleep duration and rapid decline in renal function.1 passage
• Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome.1 passage
• Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.1 passage
• Atypical chemokine receptors-"chemokine PACMANs" as new therapeutic targets in glomerulonephritis.1 passage
• Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?1 passage
• Autocrine and paracrine effects of a novel podocyte gene, RARRES1.1 passage
• Automated acute kidney injury alerts.1 passage
• Autophagy in acute kidney injury.1 passage
• Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.1 passage
• Autosomal dominant tubulointerstitial kidney disease: a new tool to guide genetic testing.1 passage
• Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report.1 passage
• Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Averting the legacy of kidney disease--focus on childhood.1 passage
• B cells regulate antidonor T-cell reactivity in transplantation.1 passage
• B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.1 passage
• B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.1 passage
• B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.1 passage
• Back off baclofen when the kidneys don't work.1 passage
• Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.1 passage
• Baclofen has a risk of encephalopathy in older adults receiving dialysis.1 passage
• Bariatric surgery for obesity-associated decline in kidney function: filling the knowledge gap?1 passage
• Bariatric surgery is associated with improvement in kidney outcomes.1 passage
• Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.1 passage
• Basic principles and new advances in kidney imaging.1 passage
• Be on alert for pediatric AKI.1 passage
• Best practices for correctly identifying coronavirus by transmission electron microscopy.1 passage
• Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal and cardiovascular complications.1 passage
• Better late than never: eventual seroconversion against SARS-CoV-2 in a kidney transplant recipient after repeated immune challenge and monoclonal antibody therapy.1 passage
• Bi-allelic pathogenic variations in DNAJB11 cause Ivemark II syndrome, a renal-hepatic-pancreatic dysplasia.1 passage
• Big data in nephrology: promises and pitfalls.1 passage
• Big science and big data in nephrology.1 passage
• Biglycan evokes autophagy in macrophages via a novel CD44/Toll-like receptor 4 signaling axis in ischemia/reperfusion injury.1 passage
• Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.1 passage
• Biomarker research to improve clinical outcomes of peritoneal dialysis: consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network.1 passage
• Biomarkers of rapid chronic kidney disease progression in type 2 diabetes.1 passage
• Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer.1 passage
• Blood pressure and kidney disease: chicken or egg (or both)?1 passage
• Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Blood pressure modifies outcomes in patients with stage 3 to 5 chronic kidney disease.1 passage
• Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease.1 passage
• Blood pressure targets for hemodialysis patients.1 passage
• Body composition is associated with clinical outcomes in patients with non-dialysis-dependent chronic kidney disease.1 passage
• Body mass index and causes of death in chronic kidney disease.1 passage
• Bone cells, sclerostin, and FGF23: what's bred in the bone will come out in the flesh.1 passage
• Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.1 passage
• Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation.1 passage
• Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.1 passage
• Bone strength: more than just bone density.1 passage
• Bones and the sex hormones.1 passage
• Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.1 passage
• Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.1 passage
• Breaking the ice: urine proteomics of medullary sponge kidney disease.1 passage
• Burnt sugarcane harvesting is associated with acute renal dysfunction.1 passage
• Buyer beware transplantation.1 passage
• C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E.1 passage
• C1q-binding donor-specific antibody assays help define risk and prognosis in antibody-mediated rejection.1 passage
• C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.1 passage
• C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.1 passage
• C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.1 passage
• CABG or PCI: which is better for revascularization of coronary artery disease in chronic kidney disease?1 passage
• CAPing inflammation and acute kidney injury.1 passage
• CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion.1 passage
• CD81 passage
• CKD in disadvantaged populations.1 passage
• CKD stage V in AL amyloidosis: is it too late to treat? Maybe not.1 passage
• COVID-19 and the multisystem inflammatory syndrome in children: how vulnerable are the kidneys?1 passage
• COVID-19 in dialysis patients: outlasting and outsmarting a pandemic.1 passage
• COVID-19 infection in kidney transplant recipients at the epicenter of pandemics.1 passage
• COVID-19 infection in kidney transplant recipients.1 passage
• COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain.1 passage
• CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis.1 passage
• CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism.1 passage
• Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis.1 passage
• Cadmium exposure enhances organic cation transporter 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity.1 passage
• Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.1 passage
• Cannabinoid receptor 1 is a major mediator of renal fibrosis.1 passage
• Cannabinoid receptor type 2 promotes kidney fibrosis through orchestrating β-catenin signaling.1 passage
• Canonical BMP signaling in tubular cells mediates recovery after acute kidney injury.1 passage
• Capillary leak syndrome: etiologies, pathophysiology, and management.1 passage
• Carbamylated sortilin associates with cardiovascular calcification in patients with chronic kidney disease.1 passage
• Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout.1 passage
• Cardiac screening prior to renal transplantation-good intentions, rather than good evidence, dictate practice.1 passage
• Cardiac surgery in patients with congenital heart disease is associated with acute kidney injury and the risk of chronic kidney disease.1 passage
• Cardiovascular events and death in Japanese patients with chronic kidney disease.1 passage
• Cardiovascular risk assessment in kidney transplantation.1 passage
• Caring for individuals with hypertension in CKD, especially those with low education.1 passage
• Cathepsins are potential therapeutic targets in kidney disease.1 passage
• Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus.1 passage
• Cellular and molecular pathways of renal repair after acute kidney injury.1 passage
• Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Challenges and opportunities for stem cell therapy in patients with chronic kidney disease.1 passage
• Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease.1 passage
• Changes in V-ATPase subunits of human urinary exosomes reflect the renal response to acute acid/alkali loading and the defects in distal renal tubular acidosis.1 passage
• Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period.1 passage
• Changes in kidney function follow living donor nephrectomy.1 passage
• Changing bone patterns with progression of chronic kidney disease.1 passage
• Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.1 passage
• Characterization of glomerular extracellular matrix by proteomic analysis of laser-captured microdissected glomeruli.1 passage
• Checkmate: kidney injury associated with targeted cancer immunotherapy.1 passage
• Chromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder.1 passage
• Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy.1 passage
• Chronic interstitial nephritis in agricultural communities is a toxin-induced proximal tubular nephropathy.1 passage
• Chronic interstitial nephritis of agricultural communities: continuing with the term CKDu (chronic kidney disease of unknown cause) is detrimental.1 passage
• Chronic kidney disease and heart disease: after 179 years, do we yet understand the link?1 passage
• Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.1 passage
• Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation.1 passage
• Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid "over"- and "under"-diagnosis of CKD.1 passage
• Chronic kidney diseases in agricultural communities: report from a workshop.1 passage
• Circulating IL-6 upregulates IL-10 production in splenic CD41 passage
• Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.1 passage
• Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.1 passage
• Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.1 passage
• Circulating factors cause proteinuria in parabiotic zebrafish.1 passage
• Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.1 passage
• Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1.1 passage
• Clinical and genetic spectra of kidney disease caused by REN mutations.1 passage
• Clinical and immunological follow-up of very long-term kidney transplant recipients treated with calcineurin inhibitors indicates dual phenotypes.1 passage
• Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies.1 passage
• Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly.1 passage
• Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening.1 passage
• Clinical markers to predict progression from acute to chronic kidney disease in Mesoamerican nephropathy.1 passage
• Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease.1 passage
• Clinical trial recommendations for potential Alport syndrome therapies.1 passage
• Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?1 passage
• Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis.1 passage
• Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis.1 passage
• Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.1 passage
• Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.1 passage
• Coagulation anomalies, endothelial dysfunction, and aortic stiffness.1 passage
• Cognitive function before and after dialysis initiation in adults with chronic kidney disease-a new perspective on an old problem?1 passage
• Cold ischemia time up to 16 hours has little impact on living donor kidney transplant outcomes in the era of kidney paired donation.1 passage
• Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney.1 passage
• Combination of mouse models and genomewide association studies highlights novel genes associated with human kidney function.1 passage
• Combination of pediatric and adult formulas yield valid glomerular filtration rate estimates in young adults with a history of pediatric chronic kidney disease.1 passage
• Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.1 passage
• Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.1 passage
• Coming out of the PiTs-novel strategies for controlling intestinal phosphate absorption in patients with CKD.1 passage
• Commentary for "human kidney pericytes produce renin".1 passage
• Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival.1 passage
• Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis.1 passage
• Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome.1 passage
• Comorbidity as a driver of adverse outcomes in people with chronic kidney disease.1 passage
• Comparative health services research across populations: the unused opportunities in big data.1 passage
• Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.1 passage
• Comparison of COVID-19 versus influenza on the incidence, features, and recovery from acute kidney injury in hospitalized United States Veterans.1 passage
• Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.1 passage
• Comparison of organ donation and transplantation rates between opt-out and opt-in systems.1 passage
• Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin.1 passage
• Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.1 passage
• Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.1 passage
• Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis.1 passage
• Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.1 passage
• Complement factor H-related proteins in IgA nephropathy-sometimes a gentle nudge does the trick.1 passage
• Complement factor H: a guardian within?1 passage
• Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.1 passage
• Complete functional characterization of disease-associated genetic variants in the complement factor H gene.1 passage
• Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury.1 passage
• Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection.1 passage
• Concerted efforts to combat diabetic complications.1 passage
• Connecting cytokines and cellular signals in the nephron during CKD and hypertension.1 passage
• Connective tissue growth factor regulates fibrosis-associated renal lymphangiogenesis.1 passage
• Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets.1 passage
• Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society.1 passage
• Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease.1 passage
• Considerations for advancing nephrology research and practice through natural language processing.1 passage
• Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.1 passage
• Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.1 passage
• Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.1 passage
• Coronary artery disease in chronic kidney disease: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage.1 passage
• Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent.1 passage
• Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.1 passage
• Corticosteroid treatment exacerbates nephrotic syndrome in a zebrafish model of magi2a knockout.1 passage
• Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.1 passage
• Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives.1 passage
• Crossroads of metabolism and CKD.1 passage
• Crosstalk between the nervous system and the kidney.1 passage
• Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.1 passage
• Current treatment practice and outcomes. Report of the hyponatremia registry.1 passage
• Cutaneous calcification in patients with kidney disease is not always calciphylaxis.1 passage
• Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy.1 passage
• Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.1 passage
• Cystinosin deficiency causes podocyte damage and loss associated with increased cell motility.1 passage
• Cystinuria: clinical practice recommendation.1 passage
• Cytosine methylation predicts renal function decline in American Indians.1 passage
• DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.1 passage
• DNA methylation yields epigenetic clues into the diabetic nephropathy of Pima Indians.1 passage
• DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.1 passage
• DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.1 passage
• Danger in the jungle: sensible care to reduce avoidable acute kidney injury in hospitalized children.1 passage
• Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.1 passage
• Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy.1 passage
• Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.1 passage
• Deceased-donor acute kidney injury is not associated with kidney allograft failure.1 passage
• Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.1 passage
• Deconstructing interstitial fibrosis and tubular atrophy: a step toward precision medicine in renal transplantation.1 passage
• Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathy.1 passage
• Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation.1 passage
• Decreased incidence of end-stage renal disease in American Indians with diabetes: a model for other high-risk populations?1 passage
• Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification.1 passage
• Deep learning identified pathological abnormalities predictive of graft loss in kidney transplant biopsies.1 passage
• Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele.1 passage
• Defective postreperfusion metabolic recovery directly associates with incident delayed graft function.1 passage
• Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping.1 passage
• Deglycosylation of myeloperoxidase uncovers its novel antigenicity.1 passage
• Delayed graft function and the risk of acute rejection in the modern era of kidney transplantation.1 passage
• Dendritic cells and innate immunity in kidney transplantation.1 passage
• Derivation and external validation of the SIMPLICITY score as a simple immune-based risk score to predict infection in kidney transplant recipients.1 passage
• Derivation and validation of genome-wide polygenic score for urinary tract stone diagnosis.1 passage
• Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.1 passage
• Development and external validation study combining existing models and recent data into an up-to-date prediction model for evaluating kidneys from older deceased donors for transplantation.1 passage
• Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy.1 passage
• Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population.1 passage
• Development and validation of a predictive mortality risk score from a European hemodialysis cohort.1 passage
• Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.1 passage
• Development and validation of a renal risk score in ANCA-associated glomerulonephritis.1 passage
• Development of a microphysiological model of human kidney proximal tubule function.1 passage
• Development of a novel cell-based assay to diagnose recurrent focal segmental glomerulosclerosis patients.1 passage
• Development of a risk stratification algorithm to improve patient-centered care and decision making for incident elderly patients with end-stage renal disease.1 passage
• Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease.1 passage
• Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys.1 passage
• Diabetes with early kidney involvement may shorten life expectancy by 16 years.1 passage
• Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.1 passage
• Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries.1 passage
• Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders.1 passage
• Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review.1 passage
• Diagnosis and treatment of arterial hypertension 2021.1 passage
• Diagnosis of complement alternative pathway disorders.1 passage
• Diagnosis of monoclonal gammopathy of renal significance.1 passage
• Diagnosis of uncertain significance: can next-generation sequencing replace the clinician?1 passage
• Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease.1 passage
• Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats.1 passage
• Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?1 passage
• Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.1 passage
• Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.1 passage
• Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease.1 passage
• Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe.1 passage
• Different sized slices of cake: macroeconomic impacts on access to transplantation and graft survival for children.1 passage
• Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo.1 passage
• Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.1 passage
• Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats.1 passage
• Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression.1 passage
• Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.1 passage
• Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity.1 passage
• Direct bone effects of calcimimetics in chronic kidney disease?1 passage
• Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.1 passage
• Direct reprogramming to human nephron progenitor-like cells using inducible piggyBac transposon expression of SNAI2-EYA1-SIX1.1 passage
• Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.1 passage
• Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.1 passage
• Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada.1 passage
• Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.1 passage
• Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1.1 passage
• Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2.1 passage
• Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy.1 passage
• Diving into the abyss of undiscovered kidney function-related factors.1 passage
• Do ANCAs make the difference in lupus nephritis?1 passage
• Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?1 passage
• Do we need to treat chronic active T cell-mediated rejection?1 passage
• Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?1 passage
• Does alanyl-glutamine supplementation offer potential to improve peritoneal dialysate biocompatibility?1 passage
• Does dialysis modality affect the development of cognitive impairment?1 passage
• Does dopamine connect the dots in ADPKD?1 passage
• Does early-start renal replacement therapy improve outcomes for patients with acute kidney injury?1 passage
• Does elastin deficiency cause chronic kidney disease?1 passage
• Does gouty nephropathy exist, and is it more common than we think?1 passage
• Does rituximab help in HLA desensitization for kidney transplantation?1 passage
• Don't trick me twice!1 passage
• Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.1 passage
• Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year.1 passage
• Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.1 passage
• Drug discovery in focal and segmental glomerulosclerosis.1 passage
• Drug repurposing in kidney disease.1 passage
• Drug-coated balloons and dialysis vascular access: is there light at the end of the tunnel . . .1 passage
• Dual lineage tracing shows that glomerular parietal epithelial cells can transdifferentiate toward the adult podocyte fate.1 passage
• Duration of chronic kidney disease reduces attention and executive function in pediatric patients.1 passage
• Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.1 passage
• Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.1 passage
• Dysfunctional HDL takes its Toll on the endothelial glycocalyx.1 passage
• EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.1 passage
• EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.1 passage
• Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation.1 passage
• Early detection of acute tubulointerstitial nephritis in the genesis of Mesoamerican nephropathy.1 passage
• Early eGFR decline after SGLT2i initiation: knowns and unknowns.1 passage
• Early hospital readmission among hemodialysis patients in the United States is associated with subsequent mortality.1 passage
• Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications.1 passage
• Eculizumab deposits in vessel walls in thrombotic microangiopathy.1 passage
• Eculizumab in children with hemolytic uremic syndrome.1 passage
• Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.1 passage
• Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.1 passage
• Effect of disease progression on the podocyte cell cycle in Alport Syndrome.1 passage
• Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.1 passage
• Effect of thiazolidinedione therapy on the risk of uric acid stones.1 passage
• Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.1 passage
• Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.1 passage
• Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.1 passage
• Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.1 passage
• Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling.1 passage
• Electronic health records for the diagnosis of rare diseases.1 passage
• Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population.1 passage
• Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.1 passage
• Elevated pulmonary pressure: A novel risk marker in kidney disease?1 passage
• Elevated serum concentrations of DNAJB9 in fibrillary glomerulonephritis: another step toward understanding a progressive disease.1 passage
• Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by1 passage
• Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes.1 passage
• Emerging role of myostatin and its inhibition in the setting of chronic kidney disease.1 passage
• Emerging roles of nuclear phosphatase SCP4 in CKD-associated muscle wasting.1 passage
• Emerging treatments for amyloidosis.1 passage
• Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.1 passage
• Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells.1 passage
• Endovascular aneurysm repair (EVAR)- and transcatheter aortic valve replacement (TAVR)-associated acute kidney injury.1 passage
• Energy sensor as a new regulator of FGF23 synthesis.1 passage
• Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin.1 passage
• Epidemiology research to foster improvement in chronic kidney disease care.1 passage
• Epidermal growth factor and kidney disease: a long-lasting story.1 passage
• Epigenetic memory in kidney diseases.1 passage
• Epigenetic regulation of RCAN1 expression in kidney disease and its role in podocyte injury.1 passage
• Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney.1 passage
• Epilepsy and antiseizure medications increase all-cause mortality in dialysis patients in the United States.1 passage
• Epithelial proliferation and cell cycle dysregulation in kidney injury and disease.1 passage
• Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression.1 passage
• Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss.1 passage
• Equitable hemodialysis for undocumented immigrant patients: prioritizing patient voices in care implementation.1 passage
• Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.1 passage
• Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops.1 passage
• Estimated aortic blood pressure based on radial artery tonometry underestimates directly measured aortic blood pressure in patients with advancing chronic kidney disease staging and increasing arterial stiffness.1 passage
• Estimating central blood pressure in the extreme vascular phenotype of advanced kidney disease.1 passage
• Estimating glomerular filtration rate at the transition from pediatric to adult care.1 passage
• Estimating residual kidney function in dialysis patients without urine collection.1 passage
• Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values.1 passage
• Ethics of kidney care in the era of COVID-19.1 passage
• Evaluating multiple living kidney donor candidates simultaneously is more cost-effective than sequentially.1 passage
• Evaluation of proteinuria redux.1 passage
• Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.1 passage
• Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.1 passage
• Evidence-based decision-making? On the limitations of Arshad et al.'s study used to justify political opinions on organ donation in Germany.1 passage
• Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.1 passage
• Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA.1 passage
• Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation.1 passage
• Executive summary for China Kidney Disease Network (CK-NET) 2016 Annual Data Report.1 passage
• Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET).1 passage
• Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.1 passage
• Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.1 passage
• Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.1 passage
• Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.1 passage
• Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.1 passage
• Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care.1 passage
• Expanding nephron progenitors in vitro: a step toward regenerative medicine in nephrology.1 passage
• Expanding the spectrum of APOL1-related renal disease: de novo collapsing glomerulopathy following kidney transplant.1 passage
• Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.1 passage
• Expanding the use of hepatitis C-viremic kidney donors.1 passage
• Expansion of polymorphonuclear myeloid-derived suppressor cells in patients with end-stage renal disease may lead to infectious complications.1 passage
• Exploring the elusive link between subclinical fibrosis and clinical events in end-stage renal disease: does cardiac magnetic resonance imaging hold the key?1 passage
• Extended hours hemodialysis and survival: extended hours, extended evidence?1 passage
• Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease.1 passage
• Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.1 passage
• Extracellular Vesicles in Kidney Transplantation: A State of the Art Review.1 passage
• Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease.1 passage
• Extracellular traps in kidney disease.1 passage
• Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy.1 passage
• FGF23 and inflammation-a vicious coalition in CKD.1 passage
• FGF23 effects on the heart-levels, time, source, and context matter.1 passage
• Facing cinacalcet-induced hypocalcemia: sit back and relax?1 passage
• Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.1 passage
• Factors leading to the discard of deceased donor kidneys in the United States.1 passage
• Failure to sense energy depletion may be a novel therapeutic target in chronic kidney disease.1 passage
• Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.1 passage
• Fatty acid-binding protein 4 downregulation drives calcification in the development of kidney stone disease.1 passage
• Ferric citrate: cardio- and renoprotective in chronic kidney disease?1 passage
• Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.1 passage
• Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism.1 passage
• Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.1 passage
• Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.1 passage
• Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.1 passage
• Fibroblast growth factor 23: fueling the fire.1 passage
• Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy?1 passage
• Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes.1 passage
• Fluid management in the critically ill.1 passage
• Folic acid supplementation and chronic kidney disease progression.1 passage
• Fractalkine-CX3CR1-dependent recruitment and retention of human CD1c+ myeloid dendritic cells by in vitro-activated proximal tubular epithelial cells.1 passage
• Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.1 passage
• Friends, social networks, and progressive chronic kidney disease.1 passage
• From bench to pet shop to bedside? The environment and immune function in mice.1 passage
• From kidney injury to kidney cancer.1 passage
• From podocyte biology to novel cures for glomerular disease.1 passage
• Full-house glomerular deposits: beware the sheep in wolf's clothing.1 passage
• Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis.1 passage
• Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.1 passage
• Functional thiamine deficiency in end-stage renal disease: malnutrition despite ample nutrients.1 passage
• Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3.1 passage
• G protein-coupled pH-sensing receptor OGR1 and metabolic acidosis-induced hypercalciuria.1 passage
• GFR after kidney donation: early recovery and subsequent decline.1 passage
• GHetting to know ADPKD proliferative signaling, STAT.1 passage
• GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.1 passage
• Gains in understanding of podocyte loss.1 passage
• Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation.1 passage
• Gasdermin D and pyroptosis in acute kidney injury.1 passage
• Gastric bypass surgery stimulates the dormant gut-brain axis in obesity.1 passage
• Gastrointestinal potassium binding in hemodialysis.1 passage
• Gastrointestinal potassium binding-more than just lowering serum [K(+)]: patiromer, potassium balance, and the renin angiotensin aldosterone axis.1 passage
• Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice.1 passage
• Genetic and clinical variables identify predictors for chronic kidney disease in type 2 diabetes.1 passage
• Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease.1 passage
• Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.1 passage
• Genetic insights into rapid kidney function decline.1 passage
• Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice.1 passage
• Genetic testing for kidney disease of unknown etiology.1 passage
• Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.1 passage
• Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci.1 passage
• Genome-wide association study of kidney function decline in individuals of European descent.1 passage
• Genome-wide association study of serum metabolites in the African American Study of Kidney Disease and Hypertension.1 passage
• Genome-wide identification of genes essential for podocyte cytoskeletons based on single-cell RNA sequencing.1 passage
• Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosis.1 passage
• Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management.1 passage
• Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.1 passage
• Geographic variation and neighborhood factors are associated with low rates of pre-end-stage renal disease nephrology care.1 passage
• Getting to know the enemy better-the global burden of chronic kidney disease.1 passage
• Gimme a complex! Resident mononuclear phagocytes in the kidney as monitors of circulating antigens and immune complexes.1 passage
• Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Global glomerulosclerosis in primary nephrotic syndrome: including age as a variable to predict renal outcomes.1 passage
• Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment.1 passage
• Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease.1 passage
• Global trends and challenges in deceased donor kidney allocation.1 passage
• Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis.1 passage
• Glomerular basement membrane nephritis: crescentic renal inflammation and immunosuppressive intervention in the time of the severe acute respiratory syndrome coronavirus 2 pandemic.1 passage
• Glomerular common gamma chain confers B- and T-cell-independent protection against glomerulonephritis.1 passage
• Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical.1 passage
• Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes.1 passage
• Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.1 passage
• GlucoCEST magnetic resonance imaging in vivo may be diagnostic of acute renal allograft rejection.1 passage
• Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.1 passage
• Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.1 passage
• Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.1 passage
• Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.1 passage
• Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor α.1 passage
• Growing a new human kidney.1 passage
• Gut microbiome and kidney stone disease: not just an Oxalobacter story.1 passage
• Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.1 passage
• Gut microbiota in renal physiology: focus on short-chain fatty acids and their receptors.1 passage
• HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.1 passage
• HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation.1 passage
• HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.1 passage
• HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.1 passage
• HLA-DQ alloantibodies directly activate the endothelium and compromise differentiation of FoxP31 passage
• Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.1 passage
• Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.1 passage
• Health disparities in access to kidney replacement therapy amongst children and adolescents with end-stage kidney disease in low- and lower-middle-income countries.1 passage
• Health-related quality of life in glomerular disease.1 passage
• Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Heavy and light chains all at once: A new immunofluorescence technique to evaluate monoclonal immunoglobulin deposits.1 passage
• Heavy metal nephropathy: considerations for exposure analysis.1 passage
• Hemodialysis patients receiving a greater Kt dose than recommended have reduced mortality and hospitalization risk.1 passage
• Hemodialysis vascular access in the elderly-getting it right.1 passage
• Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.1 passage
• Hemoglobin target in children with chronic kidney disease: valuable new information.1 passage
• Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders.1 passage
• Hepatitis C virus infection and kidney transplantation: newer options and a brighter future ahead?1 passage
• Hepatorenal syndrome: a historical appraisal of its origins and conceptual evolution.1 passage
• High and low sodium intakes are associated with incident chronic kidney disease in patients with normal renal function and hypertension.1 passage
• High cardiovascular event rates occur within the first weeks of starting hemodialysis.1 passage
• High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease.1 passage
• High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease.1 passage
• High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.1 passage
• High rates of long-term renal recovery in survivors of coronavirus disease 2019-associated acute kidney injury requiring kidney replacement therapy.1 passage
• High-density lipoprotein cholesterol on a roller coaster: where will the ride end?1 passage
• High-mobility group box 1 is a novel deacetylation target of Sirtuin1.1 passage
• High-resolution renal perfusion mapping using contrast-enhanced ultrasonography in ischemia-reperfusion injury monitors changes in renal microperfusion.1 passage
• High-throughput sequencing contributes to the diagnosis of tubulopathies and familial hypercalcemia hypocalciuria in adults.1 passage
• Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus.1 passage
• Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding.1 passage
• Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size.1 passage
• Higher diet-dependent renal acid load associates with higher glucocorticoid secretion and potentially bioactive free glucocorticoids in healthy children.1 passage
• Higher hemoglobin levels and quality of life in patients with advanced chronic kidney disease: no longer a moving target?1 passage
• Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes.1 passage
• Hippo pathway deficiency and recovery from heart failure after myocardial infarction: potential implications for kidney disease.1 passage
• Hospital readmission for the dialysis patient: who is (not) responsible?1 passage
• How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.1 passage
• How low can you go? Achieved blood pressure and cardiovascular outcomes.1 passage
• How to assess kidney function in oncology patients.1 passage
• How to interpret an estimated glomerular filtration rate (eGFR) in 2020?1 passage
• How to sharpen a novel sword from AKI basic research.1 passage
• Human and mouse studies establish TBX6 in Mendelian CAKUT and as a potential driver of kidney defects associated with the 16p11.2 microdeletion syndrome.1 passage
• Human kidney organoids produce functional renin.1 passage
• Human kidney pericytes produce renin.1 passage
• Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.1 passage
• Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cells.1 passage
• Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks.1 passage
• Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.1 passage
• Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus.1 passage
• Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans.1 passage
• Hypertension and glomerular function decline: the chicken or the egg?1 passage
• Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease.1 passage
• Hyponatremia in the cancer patient.1 passage
• Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease.1 passage
• Hypoxia signaling in renal pericytes-is it safe to activate?1 passage
• Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.1 passage
• Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification.1 passage
• Hypoxia-inducible factor-1α promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3.1 passage
• IL-17A-induced mesenchymal stem cells have promising therapeutic value for clinical translation.1 passage
• IL-17C has a pathogenic role in kidney ischemia/reperfusion injury.1 passage
• IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury.1 passage
• IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT).1 passage
• ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials.1 passage
• IdeS in anti-glomerular basement membrane disease: Is this the new deal?1 passage
• Identification of 22 novel loci associated with urinary biomarkers of albumin, sodium, and potassium excretion.1 passage
• Identification of ATP6V1C2 as a novel candidate gene for distal tubular acidosis.1 passage
• Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy.1 passage
• Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults.1 passage
• Identification of matrix metalloproteinase-10 as a key mediator of podocyte injury and proteinuria.1 passage
• Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension.1 passage
• Identification of the activating cytotoxicity receptor NKG2D as a senescence marker in zero-hour kidney biopsies is indicative for clinical outcome.1 passage
• Identifying early pathogenic events during vascular calcification in uremic rats.1 passage
• Identifying geospatial "hot spots" of glomerular diseases: opportunities and challenges.1 passage
• IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.1 passage
• IgA nephropathy: new insights into the role of complement.1 passage
• Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.1 passage
• Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney.1 passage
• Imbalance favoring follicular helper T cells over IL101 passage
• Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?1 passage
• Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System.1 passage
• Immune evasion in renal cell carcinoma: biology, clinical translation, future directions.1 passage
• Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy.1 passage
• Immunity unmasks APOL1 in collapsing glomerulopathy.1 passage
• Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases.1 passage
• Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.1 passage
• Immunosuppression in IgA nephropathy: how certain are we?1 passage
• Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants.1 passage
• Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets.1 passage
• Impact of cellular phosphate handling on vascular calcification.1 passage
• Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors.1 passage
• Impact of fluid status and inflammation and their interaction on survival: a study in an international hemodialysis patient cohort.1 passage
• Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.1 passage
• Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury.1 passage
• Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy.1 passage
• Impaired postprandial lipemic response in chronic kidney disease.1 passage
• Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease.1 passage
• Implementation of standardized follow-up care significantly reduces peritonitis in children on chronic peritoneal dialysis.1 passage
• Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.1 passage
• Implementing the European Renal Best Practice Guidelines suggests that prediction equations work well to differentiate risk of end-stage renal disease vs. death in older patients with low estimated glomerular filtration rate.1 passage
• Implications of the long interdialytic gap: a problem of excess accumulation vs. excess removal?1 passage
• Importance of bone turnover for therapeutic decisions in patients with CKD-MBD.1 passage
• Importance of reliable variant calling and clear phenotyping when reporting on gene panel testing in renal disease.1 passage
• Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.1 passage
• Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.1 passage
• Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice.1 passage
• Improved prognosis of diabetic nephropathy in type 1 diabetes.1 passage
• Improving glomerular filtration rate estimation.1 passage
• Improving human kidney function in renovascular disease with mesenchymal stem cell therapy.1 passage
• Improving kidney disease in obese adolescents: a surgical approach.1 passage
• Improving the evidence for the management of childhood nephrotic syndrome.1 passage
• Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.1 passage
• In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.1 passage
• In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy.1 passage
• In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia.1 passage
• In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.1 passage
• Inactivation of Apoptosis Antagonizing Transcription Factor in tubular epithelial cells induces accumulation of DNA damage and nephronophthisis.1 passage
• Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy.1 passage
• Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.1 passage
• Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?1 passage
• Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population.1 passage
• Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance.1 passage
• Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery.1 passage
• Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes.1 passage
• Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients.1 passage
• Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone.1 passage
• Increased soluble fms-like tyrosine kinase 1 after ischemia reperfusion contributes to adverse clinical outcomes following kidney transplantation.1 passage
• Increasing access to integrated ESKD care as part of universal health coverage.1 passage
• Increasing potassium intake to prevent kidney damage: a new population strategy?1 passage
• Increasing sodium removal on peritoneal dialysis: applying dialysis mechanics to the peritoneal dialysis prescription.1 passage
• Incremental prognostic value of kidney function decline over coronary artery disease for cardiovascular event prediction after coronary computed tomography.1 passage
• Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.1 passage
• Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization.1 passage
• Induced pluripotent stem cell-based disease modeling identifies ligand-induced decay of megalin as a cause of Donnai-Barrow syndrome.1 passage
• Induced pluripotent stem cells provide mega insights into kidney disease.1 passage
• Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality.1 passage
• Inferring causality from observational studies: the role of instrumental variable analysis.1 passage
• Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.1 passage
• Inflammation and hypoxia in the kidney: friends or foes?1 passage
• Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein δ.1 passage
• Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein-1.1 passage
• Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.1 passage
• Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.1 passage
• Inhibition of NLRP3 inflammasome as a therapeutic intervention in crystal-induced nephropathy.1 passage
• Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho.1 passage
• Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.1 passage
• Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-β in Adriamycin-induced glomerulosclerosis.1 passage
• Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis.1 passage
• Initiation of dialysis: Trigger or cause of cardiovascular events?1 passage
• Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1.1 passage
• Innate lymphoid cells in kidney diseases.1 passage
• Innovations in vascular access for hemodialysis.1 passage
• Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.1 passage
• Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.1 passage
• Insulin and the phosphatidylinositol 3-kinase signaling pathway regulate Ribonuclease 7 expression in the human urinary tract.1 passage
• Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in human and rat renal proximal tubules.1 passage
• Insulin resistance and hypertension: new insights.1 passage
• Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.1 passage
• Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.1 passage
• Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.1 passage
• Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?1 passage
• Intensive hemodialysis-keeping the faith.1 passage
• Interaction between galectin-3 and cystinosin uncovers a pathogenic role of inflammation in kidney involvement of cystinosis.1 passage
• Interaction of renal cortical cyclooxygenase-2 and angiotensin II in postnatal nephrogenesis.1 passage
• Interferon-γ production by tubulointerstitial human CD561 passage
• Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.1 passage
• Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease.1 passage
• Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.1 passage
• Interleukin-6/Stat3 signaling has an essential role in the host antimicrobial response to urinary tract infection.1 passage
• Interleukin-9 protects from early podocyte injury and progressive glomerulosclerosis in Adriamycin-induced nephropathy.1 passage
• Intermedin1-53 attenuates vascular calcification in rats with chronic kidney disease by upregulation of α-Klotho.1 passage
• International consensus definitions of clinical trial outcomes for kidney failure: 2020.1 passage
• Interpreting trial results-time for confidence and magnitude and not P values please.1 passage
• Intestinal Toll-like receptor 9 deficiency leads to Paneth cell hyperplasia and exacerbates kidney, intestine, and liver injury after ischemia/reperfusion injury.1 passage
• Intestinal lymphatic dysfunction: a new pathway mediating gut-kidney crosstalk in kidney disease.1 passage
• Intradialytic exercise improves left ventricular mass in hemodialysis patients.1 passage
• Intradialytic hypotension: is timing everything?1 passage
• Intradialytic nutrition and exercise: convenience versus efficacy.1 passage
• Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury.1 passage
• Intravenous iron administration: new observations and time for the next steps.1 passage
• Intravital phosphorescence lifetime imaging of the renal cortex accurately measures renal hypoxia.1 passage
• In vitro generation of renal tubular epithelial cells from fibroblasts: implications for precision and regenerative medicine in nephrology.1 passage
• In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling.1 passage
• Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease.1 passage
• Iron, hormesis, and protection in acute kidney injury.1 passage
• Is it time to tip your glass to prevent CKD?1 passage
• Is nephrology specialty at risk?1 passage
• Is preeclampsia a risk for end-stage renal disease?1 passage
• Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?1 passage
• Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?1 passage
• Is the peritoneal dialysis biocompatibility hypothesis dead?1 passage
• Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells.1 passage
• Ischemic brain injury in hemodialysis patients: which is more dangerous, hypertension or intradialytic hypotension?1 passage
• JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis.1 passage
• Juicing Tregs in situ to improve kidney allograft outcomes.1 passage
• KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation.1 passage
• KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer.1 passage
• Keeping the customers stratified: moving toward genetics-based treatment options in childhood NS.1 passage
• Keratins are novel markers of renal epithelial cell injury.1 passage
• Ketone bodies: back to a place in the sun.1 passage
• Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.1 passage
• Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.1 passage
• Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Kidney disease is associated with in-hospital death of patients with COVID-19.1 passage
• Kidney donation after circulatory death (DCD): state of the art.1 passage
• Kidney epithelial targeted mitochondrial transcription factor A deficiency results in progressive mitochondrial depletion associated with severe cystic disease.1 passage
• Kidney function is associated with an altered protein composition of high-density lipoprotein.1 passage
• Kidney keratins: cytoskeletal stress responders with biomarker potential.1 passage
• Kidney organoids-a new tool for kidney therapeutic development.1 passage
• Kidney outcomes three years after bariatric surgery in severely obese adolescents.1 passage
• Kidney stones are common after bariatric surgery.1 passage
• Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.1 passage
• Kidney transplant results in children: progress made, but blacks lag behind.1 passage
• Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience.1 passage
• Kidney vascular congestion exacerbates acute kidney injury in mice.1 passage
• Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?1 passage
• Kidney-on-a-chip: untapped opportunities.1 passage
• Kidney-targeted inhibition of protein kinase C-α ameliorates nephrotoxic nephritis with restoration of mitochondrial dysfunction.1 passage
• Klotho connects intermedin1-53 to suppression of vascular calcification in chronic kidney disease.1 passage
• Klotho expression in osteocytes regulates bone metabolism and controls bone formation.1 passage
• Klotho restoration via acetylation of Peroxisome Proliferation-Activated Receptor γ reduces the progression of chronic kidney disease.1 passage
• Klotho upregulation by rapamycin protects against vascular disease in CKD.1 passage
• Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice.1 passage
• Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines.1 passage
• Knowing your GFR-when is the number not (exactly) the number?1 passage
• Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose.1 passage
• L-lactic acidosis: pathophysiology, classification, and causes; emphasis on biochemical and metabolic basis.1 passage
• LAPping up dead cells to prevent lupus nephritis: a novel role for noncanonical autophagy in autoimmunity.1 passage
• Label-free molecular imaging of the kidney.1 passage
• Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy.1 passage
• Lessons from a rare disease: IgG subclass and disease severity in alloimmune antenatal membranous nephropathy.1 passage
• Letter regarding "Estimated aortic blood pressure based on radial artery tonometry underestimates directly measured aortic blood pressure in patients with advancing chronic kidney disease staging and increasing arterial stiffness".1 passage
• Leukocyte-derived microvesicles dock on glomerular endothelial cells: stardust in the kidney.1 passage
• Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug.1 passage
• Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand?1 passage
• Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.1 passage
• Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?1 passage
• Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone.1 passage
• Limited health literacy in advanced kidney disease.1 passage
• Limited health literacy is associated with reduced access to kidney transplantation.1 passage
• Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial.1 passage
• Lipids, inflammation, and chronic kidney disease: a SHARP perspective.1 passage
• Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.1 passage
• Lipopolysaccharide induces filtrate leakage from renal tubular lumina into the interstitial space via a proximal tubular Toll-like receptor 4-dependent pathway and limits sensitivity to fluid therapy in mice.1 passage
• Lithocholic acid increases intestinal phosphate and calcium absorption in a vitamin D receptor dependent but transcellular pathway independent manner.1 passage
• Little fish, big catch: zebrafish as a model for kidney disease.1 passage
• Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere.1 passage
• Local complement factor H protects kidney endothelial cell structure and function.1 passage
• Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?1 passage
• Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.1 passage
• Long-term graft outcomes and patient survival are lower posttransplant in patients with a primary renal diagnosis of glomerulonephritis.1 passage
• Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.1 passage
• Long-term outcome of kidney transplantation in AL amyloidosis.1 passage
• Long-term outcomes after AKI-a major unmet clinical need.1 passage
• Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy.1 passage
• Long-term outcomes of end-stage kidney disease for patients with lupus nephritis.1 passage
• Long-term renal allograft survival: a quiet revolution.1 passage
• Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure.1 passage
• Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.1 passage
• Long-term trends in the prevalence of chronic kidney disease and the influence of cardiovascular risk factors in Norway.1 passage
• Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.1 passage
• Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.1 passage
• Longitudinal bioimpedance vector plots add little value to fluid management of peritoneal dialysis patients.1 passage
• Losing their footing: Rac1 signaling causes podocyte detachment and FSGS.1 passage
• Loss of Glis2/NPHP7 causes kidney epithelial cell senescence and suppresses cyst growth in the Kif3a mouse model of cystic kidney disease.1 passage
• Loss of executive function after dialysis initiation in adults with chronic kidney disease.1 passage
• Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation.1 passage
• Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease.1 passage
• Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice.1 passage
• Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients.1 passage
• Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression.1 passage
• Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children.1 passage
• Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.1 passage
• Low potassium excretion but not high sodium excretion is associated with increased risk of developing chronic kidney disease.1 passage
• Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.1 passage
• Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.1 passage
• Lrig2 and Hpse2, mutated in urofacial syndrome, pattern nerves in the urinary bladder.1 passage
• Lymphangiogenesis in a mouse model of renal transplant rejection extends life span of the recipients.1 passage
• Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.1 passage
• Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.1 passage
• M2 macrophages in kidney disease: biology, therapies, and perspectives.1 passage
• Machine learning, the kidney, and genotype-phenotype analysis.1 passage
• Machine-learning algorithms define pathogen-specific local immune fingerprints in peritoneal dialysis patients with bacterial infections.1 passage
• Macrophage density in early surveillance biopsies predicts future renal transplant function.1 passage
• Magnesium as a Janus-faced inhibitor of calcification.1 passage
• Magnesium as a new player in CKD: too little is as bad as too much?1 passage
• Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease.1 passage
• Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.1 passage
• Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients.1 passage
• Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation.1 passage
• Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Management of acute kidney injury in symptomatic multiple myeloma.1 passage
• Management of fluid overload in hemodialysis patients.1 passage
• Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Managing atypical hemolytic uremic syndrome: chapter 2.1 passage
• Manipulating the gut microbiome to decrease uremic toxins.1 passage
• Manipulating the microbiome.1 passage
• Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.1 passage
• Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes.1 passage
• Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders.1 passage
• Maternal alloimmune IgG causes anti-glomerular basement membrane disease in perinatal transgenic mice that express human laminin α5.1 passage
• Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation.1 passage
• Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration.1 passage
• Measurement of innate immune response biomarkers in peritoneal dialysis effluent using a rapid diagnostic point-of-care device as a diagnostic indicator of peritonitis.1 passage
• Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease.1 passage
• Measuring glomerular filtration rate with iohexol plasma disappearance: blood collection duration is essential for accurate glomerular filtration rate determinations.1 passage
• Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections?1 passage
• Measuring the patient response to dialysis therapy: hemodiafiltration and clinical trials.1 passage
• Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.1 passage
• Mechanisms of vascular dysfunction in the interleukin-10-deficient murine model of preeclampsia indicate nitric oxide dysregulation.1 passage
• Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.1 passage
• Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease.1 passage
• Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits.1 passage
• Membranous nephropathy: integrating basic science into improved clinical management.1 passage
• Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease.1 passage
• Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics.1 passage
• Mesenchymal stromal cell-based therapies for acute kidney injury: progress in the last decade.1 passage
• Mesoamerican nephropathy: pathology in search of etiology.1 passage
• Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.1 passage
• Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.1 passage
• Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population.1 passage
• Metabolome-wide association study of estimated glomerular filtration rates in Hispanics.1 passage
• Metabolomics assessment reveals oxidative stress and altered energy production in the heart after ischemic acute kidney injury in mice.1 passage
• Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis.1 passage
• Metformin and other antidiabetic agents in renal failure patients.1 passage
• Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.1 passage
• Methodological challenges when carrying out research on CKD and AKI using routine electronic health records.1 passage
• Methodological issues in current practice may lead to bias in the development of biomarker combinations for predicting acute kidney injury.1 passage
• Mice with mutant Inf2 show impaired podocyte and slit diaphragm integrity in response to protamine-induced kidney injury.1 passage
• MicroRNA-214 promotes chronic kidney disease by disrupting mitochondrial oxidative phosphorylation.1 passage
• MicroRNAs in extracellular vesicles protect kidney from ischemic injury: from endothelial to tubular epithelial.1 passage
• Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI.1 passage
• Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis.1 passage
• Migration of smooth muscle cells from the arterial anastomosis of arteriovenous fistulas requires Notch activation to form neointima.1 passage
• Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife.1 passage
• Mineral and bone disorder in chronic kidney disease: pioneering studies.1 passage
• Mineral bone disease in autosomal dominant polycystic kidney disease.1 passage
• Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.1 passage
• Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease.1 passage
• Mining the human urine proteome for monitoring renal transplant injury.1 passage
• Mitochondrial DNA copy number is associated with mortality and infections in a large cohort of patients with chronic kidney disease.1 passage
• Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury.1 passage
• Mitochondrial dysfunction in obesity-related kidney disease: a novel therapeutic target.1 passage
• Modeling human disease: a mouse model of acute kidney injury to chronic kidney disease progression after cardiac arrest.1 passage
• Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.1 passage
• Modulation of transforming growth factor-β-induced kidney fibrosis by leucine-rich ⍺-2 glycoprotein-1.1 passage
• Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes.1 passage
• Molecular mechanisms of renal aging.1 passage
• Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?1 passage
• Monitoring acid base status in CKD patients: can urinary citrate help?1 passage
• Monogenic causes of chronic kidney disease in adults.1 passage
• Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.1 passage
• Moore's law for membranous nephropathy.1 passage
• Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease.1 passage
• More frequent hemodialysis does not effectively clear protein-bound azotemic solutes derived from gut microbiome metabolism.1 passage
• More than ever, efficient evaluation of potential living kidney donors is needed.1 passage
• More trouble with FGF23: a novel role in systemic immunosuppression.1 passage
• Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation.1 passage
• Mortality risk in European children with end-stage renal disease on dialysis.1 passage
• Moving East: the Euro-Lupus Nephritis regimen in Asia.1 passage
• Mucosal corticosteroid therapy of IgA nephropathy.1 passage
• Multidisciplinary approaches for elucidating genetics and molecular pathogenesis of urinary tract malformations.1 passage
• Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases.1 passage
• Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.1 passage
• Multimodal Eph/Ephrin signaling controls several phases of urogenital development.1 passage
• Multiparametric magnetic resonance imaging shows promising results to assess renal transplant dysfunction with fibrosis.1 passage
• Multiphasic effects of blood pressure on survival in hemodialysis patients.1 passage
• Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.1 passage
• Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.1 passage
• Mutations in KIRREL1, a slit diaphragm component, cause steroid-resistant nephrotic syndrome.1 passage
• Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.1 passage
• Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury.1 passage
• NELL1 is a target antigen in malignancy-associated membranous nephropathy.1 passage
• NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling.1 passage
• NODding off in acute kidney injury with progranulin?1 passage
• NPHP1 gene-associated nephronophthisis is associated with an occult retinopathy.1 passage
• Nanomedicines for kidney diseases.1 passage
• National and international kidney failure registries: characteristics, commonalities, and contrasts.1 passage
• National trends in acute kidney injury requiring dialysis in England between 1998 and 2013.1 passage
• Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.1 passage
• Natural killers: the bad guys in fibrosis?1 passage
• Natural language processing of electronic health records is superior to billing codes to identify symptom burden in hemodialysis patients.1 passage
• Natural regulatory T cells from patients with end-stage renal disease can be used for large-scale generation of highly suppressive alloantigen-specific Tregs.1 passage
• Necroptosis and parthanatos are involved in remote lung injury after receiving ischemic renal allografts in rats.1 passage
• Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria.1 passage
• Nephron reconstitution from pluripotent stem cells.1 passage
• Nephrotic syndrome in pregnancy poses risks with both maternal and fetal complications.1 passage
• Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.1 passage
• Net K1 passage
• Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.1 passage
• Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.1 passage
• Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis.1 passage
• Neutrophil extracellular traps in ischemic AKI: new way to kill.1 passage
• Neutrophil serine proteases exert proteolytic activity on endothelial cells.1 passage
• Neutrophils in cisplatin AKI-mediator or marker?1 passage
• New GFR-estimating equations for children and young adults in North America and Europe.1 passage
• New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis.1 passage
• New developments in the diagnosis of fibrillary glomerulonephritis.1 passage
• New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.1 passage
• New drug toxicities in the onco-nephrology world.1 passage
• New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.1 passage
• New insights into mechanisms of glomerular injury and repair from the 10th International Podocyte Conference 2014.1 passage
• New insights into precursors of renal endothelium.1 passage
• New insights into the pathogenesis and treatment of heavy chain deposition disease.1 passage
• New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy.1 passage
• New pathogenic insights inform therapeutic target development for renal osteodystrophy.1 passage
• New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.1 passage
• New zebrafish model for monitoring proximal tubule physiology in genetic and acquired renal Fanconi syndromes.1 passage
• Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease.1 passage
• Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.1 passage
• No increase in the incidence of acute kidney injury in a population-based annual temporal trends epidemiology study.1 passage
• Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference.1 passage
• Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.1 passage
• Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity.1 passage
• Non-HLA antibodies targeting angiotensin II type 1 receptors and endothelin-1 type A receptors impair endothelial repair via a β2-arrestin link to the mTOR pathway.1 passage
• Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney.1 passage
• Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease.1 passage
• Nonapoptotic cell death in acute kidney injury and transplantation.1 passage
• Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis.1 passage
• Noncoding RNAs in acute kidney injury.1 passage
• Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.1 passage
• Normal body mass index with central obesity has increased risk of coronary artery calcification in Korean patients with chronic kidney disease.1 passage
• Normalizing the peritoneal dialysis dose-have we got it right?1 passage
• Not all vascular smooth muscle cell exosomes calcify equally in chronic kidney disease.1 passage
• Notch signaling in bone marrow-derived FSP-1 cells initiates neointima formation in arteriovenous fistulas.1 passage
• Notch3 orchestrates epithelial and inflammatory responses to promote acute kidney injury.1 passage
• Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.1 passage
• Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation.1 passage
• Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.1 passage
• Novel aspects of epitope matching and practical application in kidney transplantation.1 passage
• Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients.1 passage
• Novel clinical manifestations and treatment of hereditary apoA-I amyloidosis: when a good protein turns bad.1 passage
• Novel mutations in the inverted formin 2 gene of Chinese families contribute to focal segmental glomerulosclerosis.1 passage
• Novel nephronophthisis-associated variants reveal functional importance of MAPKBP1 dimerization for centriolar recruitment.1 passage
• Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions.1 passage
• Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease.1 passage
• Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research.1 passage
• Now or never? The case for cell-based immunosuppression in kidney transplantation.1 passage
• Nuclear antigen-reactive CD41 passage
• Obesity and kidney disease: from population to basic science and the search for new therapeutic targets.1 passage
• Obesity and kidney disease: hidden consequences of the epidemic.1 passage
• Obesity increases the risk of end-stage renal disease among living kidney donors.1 passage
• Obesity, metabolic health, and the risk of end-stage renal disease.1 passage
• Observations of a large Dent disease cohort.1 passage
• Observations of twice a week hemodialysis.1 passage
• Of mice and women: do sex-dependent responses to ischemia-reperfusion injury in rodents have implications for delayed graft function in humans?1 passage
• Oh cystinosin: let me count the ways!1 passage
• On the need to better protect hemodialysis patients: a comment on "IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)".1 passage
• Once upon a time in dialysis: the last days of Kt/V?1 passage
• Opt-out legislations: the mysterious viability of the false.1 passage
• Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration.1 passage
• Oral or intravenous iron for anemia correction in chronic kidney disease?1 passage
• Organelle crosstalk in the kidney.1 passage
• Origin of myofibroblasts and cellular events triggering fibrosis.1 passage
• Osteocyte dysfunction and renal osteodystrophy: not just calcium and phosphorus anymore.1 passage
• Outcomes and renal function trajectory after acute kidney injury: the narrow road to perdition.1 passage
• Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.1 passage
• Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.1 passage
• PCSK9 inhibition: ready for prime time in CKD?1 passage
• PHD in the FOXD1 lineage cells links hypoxia to inappropriate nephrogenesis.1 passage
• Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response.1 passage
• Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias.1 passage
• Parathyroid hormone metabolism and signaling in health and chronic kidney disease.1 passage
• Parathyroid hormone oxidation in chronic kidney disease: clinical relevance?1 passage
• Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.1 passage
• Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.1 passage
• Patient perspectives and involvement in precision medicine research.1 passage
• Patient-reported outcomes and experiences in the transition of undocumented patients from emergency to scheduled hemodialysis.1 passage
• Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study.1 passage
• Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.1 passage
• Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis.1 passage
• Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities.1 passage
• Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.1 passage
• Patients with primary membranous nephropathy are at high risk of cardiovascular events.1 passage
• Performance of creatinine- or cystatin C-based equations to estimate glomerular filtration rate in sub-Saharan African populations.1 passage
• Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery.1 passage
• Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery.1 passage
• Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course.1 passage
• Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease.1 passage
• Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes.1 passage
• Peritoneal or hemodialysis for the frail elderly patient, the choice of 2 evils?1 passage
• Peritubular capillaries: an important piece of the puzzle.1 passage
• Peritubular capillaritis in the renal allograft takes center stage.1 passage
• Persistent and inducible neogenesis repopulates progenitor renin lineage cells in the kidney.1 passage
• Personalized dynamic risk assessment in nephrology is a next step in prognostic research.1 passage
• Phasor approach to autofluorescence lifetime imaging FLIM can be a quantitative biomarker of chronic renal parenchymal injury.1 passage
• Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.1 passage
• Phenotype standardization for drug-induced kidney disease.1 passage
• Phosphate enemas and GFR decline: it's premature to sound the alarm.1 passage
• Phosphate meeting cholesterol-consequences for cardiovascular disease in chronic kidney disease?1 passage
• Phosphate-a poison for humans?1 passage
• Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway.1 passage
• Planar cell polarity genes Celsr1 and Vangl2 are necessary for kidney growth, differentiation, and rostrocaudal patterning.1 passage
• Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.1 passage
• Plasma cadmium is associated with increased risk of long-term kidney graft failure.1 passage
• Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.1 passage
• Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.1 passage
• Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.1 passage
• Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.1 passage
• Plasmacytoid dendritic cells: important players in human kidney allograft rejection.1 passage
• Plasmapheresis for the treatment of kidney diseases.1 passage
• Platelet retention in inflamed glomeruli occurs via selective prolongation of interactions with immune cells.1 passage
• Podocyte development, disease, and stem cell research.1 passage
• Podocyte injury and its consequences.1 passage
• Podocyte stress and detachment measured in urine are related to mean arterial pressure in healthy humans.1 passage
• Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.1 passage
• Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases.1 passage
• Point-of-care ultrasound in the practice of nephrology.1 passage
• Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans.1 passage
• Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation.1 passage
• Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.1 passage
• Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension.1 passage
• Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy.1 passage
• Post-discharge kidney function is associated with subsequent ten-year renal progression risk among survivors of acute kidney injury.1 passage
• Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.1 passage
• Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.1 passage
• Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.1 passage
• Potassium channels in control of renal function.1 passage
• Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.1 passage
• Potential relevance of shear stress for slit diaphragm and podocyte function.1 passage
• Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties.1 passage
• Pre-admission proteinuria impacts risk of non-recovery after dialysis-requiring acute kidney injury.1 passage
• Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease.1 passage
• Precision nosology versus precision nephrology: defining acute kidney injury, again.1 passage
• Prediabetes after kidney transplantation-a reason to worry?1 passage
• Prediabetes is a risk factor for cardiovascular disease following renal transplantation.1 passage
• Predicting long-term kidney allograft outcomes: pitfalls and progress.1 passage
• Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin.1 passage
• Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.1 passage
• Prediction Models of Treatment Response in Lupus Nephritis.1 passage
• Prediction and validation of hemodialysis duration in acute methanol poisoning.1 passage
• Prediction and validation of the duration of hemodialysis sessions for the treatment of acute ethylene glycol poisoning.1 passage
• Prediction modeling-part 1: regression modeling.1 passage
• Prediction modeling-part 2: using machine learning strategies to improve transplantation outcomes.1 passage
• Predilution online hemodiafiltration is associated with improved survival compared with hemodialysis.1 passage
• Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease.1 passage
• Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.1 passage
• Pregnancy across the spectrum of chronic kidney disease.1 passage
• Pregnancy in chronic kidney disease and kidney transplantation.1 passage
• Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.1 passage
• Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time.1 passage
• Preservation of residual kidney function in hemodialysis patients: reviving an old concept.1 passage
• Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome.1 passage
• Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients.1 passage
• Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease.1 passage
• Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients.1 passage
• Preventing peritoneal membrane fibrosis in peritoneal dialysis patients.1 passage
• Prevention and treatment of hyperphosphatemia in chronic kidney disease.1 passage
• Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines.1 passage
• Prevention of apoptosis averts glomerular tubular disconnection and podocyte loss in proteinuric kidney disease.1 passage
• Preventive nephrology in the era of "I" evidence: should we screen for chronic kidney disease?1 passage
• Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo.1 passage
• Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.1 passage
• Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.1 passage
• Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).1 passage
• Prioritization and burden analysis of rare variants in 208 candidate genes suggest they do not play a major role in CAKUT.1 passage
• Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects.1 passage
• Probiotics and chronic kidney disease.1 passage
• Prognostic assessment of IgA nephropathy: how much does histology add?1 passage
• Progranulin protects against renal ischemia/reperfusion injury in mice.1 passage
• Progression of chronic kidney disease: too much cellular talk causes damage.1 passage
• Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.1 passage
• Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.1 passage
• Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.1 passage
• Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation.1 passage
• Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.1 passage
• Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?1 passage
• Promising biomarkers for superimposed pre-eclampsia in pregnant women with established hypertension and chronic kidney disease.1 passage
• Properdin binds independent of complement activation in an in vivo model of anti-glomerular basement membrane disease.1 passage
• Prophylactic hydration to prevent contrast-induced nephropathy: much ado about nothing?1 passage
• Protein carbamylation and cardiovascular disease.1 passage
• Protein carbamylation exacerbates vascular calcification.1 passage
• Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.1 passage
• Protein carbamylation: a key driver of vascular calcification during chronic kidney disease.1 passage
• Protein kinase C α inhibition prevents peritoneal damage in a mouse model of chronic peritoneal exposure to high-glucose dialysate.1 passage
• Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism.1 passage
• Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance.1 passage
• Proteomic-based research strategy identified laminin subunit alpha 2 as a potential urinary-specific biomarker for the medullary sponge kidney disease.1 passage
• Proton pump inhibitors and chronic kidney disease: is it time to sound the alarm?1 passage
• Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far?1 passage
• Proximal tubule cyclophilin D regulates fatty acid oxidation in cisplatin-induced acute kidney injury.1 passage
• Pumping iron in the kidney.1 passage
• Purinergic signaling in kidney disease.1 passage
• Pyrophosphate deficiency in vascular calcification.1 passage
• Quantification of nonosmotic sodium storage capacity following acute hypertonic saline infusion in healthy individuals.1 passage
• Questionable specificity of histologic findings in calcific uremic arteriolopathy.1 passage
• RGS4 inhibits angiotensin II signaling and macrophage localization during renal reperfusion injury independent of vasospasm.1 passage
• RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance.1 passage
• Rac1 activation in podocytes induces the spectrum of nephrotic syndrome.1 passage
• Race but not Hepatitis C co-infection affects survival of HIV1 passage
• Racial and ethnic disparities in pediatric renal allograft survival in the United States.1 passage
• Radiographic absorptiometry: a step in solving the CKD fracture puzzle.1 passage
• Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.1 passage
• Rare inherited disorders with renal involvement-approach to the patient.1 passage
• Rationale and design of the Kidney Precision Medicine Project.1 passage
• Reaching consensus on the important outcomes for peritoneal dialysis patients.1 passage
• Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease.1 passage
• Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure.1 passage
• Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation.1 passage
• Recent developments in epigenetics of acute and chronic kidney diseases.1 passage
• Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice.1 passage
• Recognizing diversity in parietal epithelial cells.1 passage
• Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.1 passage
• Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee.1 passage
• Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning.1 passage
• Recurrence of glomerulonephritis: an underestimated and unmet medical need.1 passage
• Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.1 passage
• Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.1 passage
• Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk.1 passage
• Recycling to discover something new: the role of autophagy in kidney disease.1 passage
• Reduced Krüppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy.1 passage
• Reduced Lon protease 1 expression in podocytes contributes to the pathogenesis of podocytopathy.1 passage
• Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria.1 passage
• Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease.1 passage
• Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function.1 passage
• Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease.1 passage
• Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants.1 passage
• Refining insulin signaling in the proximal tubule at the level of the substrate.1 passage
• Regarding "Combination of pediatric and adult formulas yield valid glomerular filtration rate estimates in young adults with a history of pediatric chronic kidney disease".1 passage
• Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries.1 passage
• Regenerative medicine in kidney disease.1 passage
• Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.1 passage
• Regulated necrosis in kidney ischemia-reperfusion injury.1 passage
• Regulatory T cells in kidney disease and transplantation.1 passage
• Regulatory innate lymphoid cells suppress innate immunity and reduce renal ischemia/reperfusion injury.1 passage
• Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.1 passage
• Relationship between patients' outcomes and the changes in serum creatinine and urine output and RIFLE classification in a large critical care cohort database.1 passage
• Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.1 passage
• Release of extracellular DNA influences renal ischemia reperfusion injury by platelet activation and formation of neutrophil extracellular traps.1 passage
• Remote ischemic preconditioning has a neutral effect on the incidence of kidney injury after coronary artery bypass graft surgery.1 passage
• Renal biopsy findings in patients with extreme obesity: more heterogeneous than you think.1 passage
• Renal blood flow and acute kidney injury in septic shock: an arduous conflict that smolders intrarenally?1 passage
• Renal cell carcinoma for the nephrologist.1 passage
• Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.1 passage
• Renal dysfunction is already evident within the first month of life in Australian Indigenous infants born preterm.1 passage
• Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System.1 passage
• Renal function in relation to sodium intake: a quantitative review of the literature.1 passage
• Renal globotriaosylceramide facilitates tubular albumin absorption and its inhibition protects against acute kidney injury.1 passage
• Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.1 passage
• Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.1 passage
• Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.1 passage
• Renal perfusion in sepsis: from macro- to microcirculation.1 passage
• Renal peroxiredoxin 6 interacts with anion exchanger 1 and plays a novel role in pH homeostasis.1 passage
• Renal potassium physiology: integration of the renal response to dietary potassium depletion.1 passage
• Renal systems biology of patients with systemic inflammatory response syndrome.1 passage
• Renal transplant recipients receiving loop diuretic therapy have increased urinary tract infection rate and altered medullary macrophage polarization marker expression.1 passage
• Renal tubular lysosomal vacuoles are a generic toxic manifestation and not particularly associated with agrochemicals and heavy metal toxicity or specific to a disease.1 passage
• Renal tubule injury: a driving force toward chronic kidney disease.1 passage
• Renin-angiotensin aldosterone inhibitor use at hospital discharge among patients with moderate to severe acute kidney injury and its association with recurrent acute kidney injury and mortality.1 passage
• Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.1 passage
• Repeat kidney biopsy for lupus nephritis: an important step forward.1 passage
• Replenishment of the podocyte compartment by parietal epithelial cells.1 passage
• Repression of CMIP transcription by WT1 is relevant to podocyte health.1 passage
• Residual renal function: a paradigm shift.1 passage
• Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant.1 passage
• Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease.1 passage
• Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.1 passage
• Results from the German Chronic Kidney Disease (GCKD) study support association of relative telomere length with mortality in a large cohort of patients with moderate chronic kidney disease.1 passage
• Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring.1 passage
• Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery.1 passage
• Results from the randomized controlled IHOPE trial suggest no effects of oral protein supplementation and exercise training on physical function in hemodialysis patients.1 passage
• Results in the ESPN/ERA-EDTA Registry suggest disparities in access to kidney transplantation but little variation in graft survival of children across Europe.1 passage
• Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.1 passage
• Results of an explorative clinical evaluation suggest immediate and persistent post-reperfusion metabolic paralysis drives kidney ischemia reperfusion injury.1 passage
• Results of the CARDIA study suggest that higher dietary potassium may be kidney protective.1 passage
• Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.1 passage
• Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.1 passage
• Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children.1 passage
• Resuscitation for the specialty of nephrology: is cardionephrology the answer?1 passage
• Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor α.1 passage
• Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.1 passage
• Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.1 passage
• Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference.1 passage
• Revisiting RAAS blockade in CKD with newer potassium-binding drugs.1 passage
• Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells.1 passage
• Revisiting the determinants of the glomerular filtration barrier: what goes round must come round.1 passage
• Rhabdomyolysis and complement-once again, epithelial cells take center stage.1 passage
• Rho GTPase regulatory proteins in podocytes.1 passage
• Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate gene for monogenic focal segmental glomerulosclerosis.1 passage
• Ribonucleases 6 and 7 have antimicrobial function in the human and murine urinary tract.1 passage
• Risk HLA class II alleles and amino acid residues in myeloperoxidase-ANCA-associated vasculitis.1 passage
• Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis.1 passage
• Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies.1 passage
• Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate.1 passage
• Risk scores-the modern Oracle of Delphi?1 passage
• Role of direct oral anticoagulants in patients with kidney disease.1 passage
• Role of proteinuria in the anemia of chronic kidney disease.1 passage
• Role of proton receptor OGR1 in bone response to metabolic acidosis?1 passage
• Roscovitine blocks collecting duct cyst growth in Cep164-deficient kidneys.1 passage
• SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule.1 passage
• SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease.1 passage
• SGLT-2 inhibition in IgA nephropathy: the new standard of care?1 passage
• SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?1 passage
• SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.1 passage
• SON haploinsufficiency causes impaired pre-mRNA splicing of CAKUT genes and heterogeneous renal phenotypes.1 passage
• STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease.1 passage
• Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.1 passage
• Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.1 passage
• Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?1 passage
• Salbutamol and salt-sensitive hypertension.1 passage
• Salt and health: time to revisit the recommendations.1 passage
• Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.1 passage
• Salt, water, and vasopressin in polycystic kidney disease.1 passage
• Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis.1 passage
• Schlöndorff and Lee revealed crosstalk between glomerular cells and a role of BAMBI in diabetic kidney disease.1 passage
• Sclerostin and DKK1: new players in renal bone and vascular disease.1 passage
• Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.1 passage
• Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective.1 passage
• Screening for muscle wasting and dysfunction in patients with chronic kidney disease.1 passage
• Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Secondary IgA nephropathy.1 passage
• Secondary atypical hemolytic uremic syndromes in the era of complement blockade.1 passage
• Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.1 passage
• Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.1 passage
• Sensing the texture of imaging, a new biomarker of polycystic kidney disease.1 passage
• Sequencing rare and common APOL1 coding variants to determine kidney disease risk.1 passage
• Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis.1 passage
• Serum amyloid P deposition is a sensitive and specific feature of membranous-like glomerulopathy with masked IgG kappa deposits.1 passage
• Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.1 passage
• Serum levels of the adipokine zinc-alpha2-glycoprotein (ZAG) predict mortality in hemodialysis patients.1 passage
• Serum metabolites are associated with all-cause mortality in chronic kidney disease.1 passage
• Setting the limit for living kidney donation-how big is too big?1 passage
• Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.1 passage
• Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?1 passage
• Sex hormone-binding globulin is a biomarker associated with nonvertebral fracture in men on dialysis therapy.1 passage
• Shared decision-making in hemodialysis vascular access practice.1 passage
• Shifting paradigms in eligibility criteria for live kidney donation: a systematic review.1 passage
• Short daily-, nocturnal- and conventional-home hemodialysis have similar patient and treatment survival.1 passage
• Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?1 passage
• Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.1 passage
• Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations.1 passage
• Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation.1 passage
• Silent diabetic nephropathy.1 passage
• Simplifying the hemodialysis prescription in patients with ethylene glycol poisoning.1 passage
• Simultaneous glomerular filtration rate determination using inulin, iohexol, and1 passage
• Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies.1 passage
• Single-nephron proteomes connect morphology and function in proteinuric kidney disease.1 passage
• Sirtuin 6 and renal injury: another link in the β-catenin chain?1 passage
• Sirtuin and metabolic kidney disease.1 passage
• Sleepless in CKD: a novel risk factor for CKD progression?1 passage
• Small RNAs pack a punch in human kidney disease.1 passage
• Smaller caliber renal arteries are a novel feature of uromodulin-associated kidney disease.1 passage
• Smoking increases the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease.1 passage
• Social deprivation is associated with poor kidney transplantation outcome in children.1 passage
• Sodium and water handling during hemodialysis: new pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease.1 passage
• Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.1 passage
• Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.1 passage
• Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.1 passage
• Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.1 passage
• Sox11 gene disruption causes congenital anomalies of the kidney and urinary tract (CAKUT).1 passage
• Speculations on salt and the genesis of arterial hypertension.1 passage
• Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model.1 passage
• Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease.1 passage
• Spot urine versus 24-hour urine collection for estimation of the generation of uremic toxins originating from gut microbial metabolism.1 passage
• Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.1 passage
• Statins, obesity, and the microbiome: a potential mechanism for the pleiotropic effects of statin therapy.1 passage
• Stem cell sheet therapy: another option for acute kidney injury?1 passage
• Steps on the Alport path to proteinuria.1 passage
• Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome.1 passage
• Stimulation of erythropoietin release by hypoxia and hypoxemia: similar but different.1 passage
• Strategic plan for integrated care of patients with kidney failure.1 passage
• Strategies for the optimal timing to start renal replacement therapy in critically ill patients with acute kidney injury.1 passage
• Strategies that improve renal medullary oxygenation during experimental cardiopulmonary bypass may mitigate postoperative acute kidney injury.1 passage
• Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.1 passage
• Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.1 passage
• Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.1 passage
• Subclinical pulmonary congestion is prevalent in nephrotic syndrome.1 passage
• Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.1 passage
• Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis.1 passage
• Suggestions for the prevention of Clostridioides difficile spread within outpatient hemodialysis facilities.1 passage
• Summary of the International Conference on Onco-Nephrology: an emerging field in medicine.1 passage
• Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients.1 passage
• Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients.1 passage
• Superoxide and hydrogen peroxide counterregulate myogenic contractions in renal afferent arterioles from a mouse model of chronic kidney disease.1 passage
• Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients.1 passage
• Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe.1 passage
• Surgical intervention for urolithiasis: does it result in long-term medical complications?1 passage
• Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not.1 passage
• Survival improvements for Europeans with ESKD.1 passage
• Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease.1 passage
• Syndecan-4: major player or innocent bystander of the endothelial glycocalyx?1 passage
• T-cell exhaustion correlates with improved outcomes in kidney transplant recipients.1 passage
• TAMEing ADPKD with metformin: safe and effective?1 passage
• TNF receptors: signaling pathways and contribution to renal dysfunction.1 passage
• TRPC6 and kidney disease: sclerosing more than just glomeruli?1 passage
• TRPV5 in renal tubular calcium handling and its potential relevance for nephrolithiasis.1 passage
• Take my breath away: necrosis in kidney transplants kills the lungs!1 passage
• Talking back: the podocytes and endothelial cells duke it out.1 passage
• Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition.1 passage
• Targeting PIs to improve PTs:a new approach to treating genetic diseases of the proximal tubule.1 passage
• Targeting TMEM16A-encoded Ca1 passage
• Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosis.1 passage
• Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α.1 passage
• Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism.1 passage
• Targeting serum calcium in chronic kidney disease and end-stage renal disease: is normal too high?1 passage
• Targeting the complement cascade: novel treatments coming down the pike.1 passage
• Targeting the fatty acid transport protein CD36, a class B scavenger receptor, in the treatment of renal disease.1 passage
• Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.1 passage
• Telenephrology: current perspectives and future directions.1 passage
• Telling the tiger by its stripes: mapping the genomics of kidney graft tolerance in real time.1 passage
• Telomere length and chronic kidney disease: cause or consequence?1 passage
• Tenascin-C promotes acute kidney injury to chronic kidney disease progression by impairing tubular integrity via αvβ6 integrin signaling.1 passage
• Tenascin-C protects against acute kidney injury by recruiting Wnt ligands.1 passage
• The (pro)renin receptor: an emerging player in hypertension and metabolic syndrome.1 passage
• The AGES-Reykjavik Study suggests that change in kidney measures is associated with subclinical brain pathology in older community-dwelling persons.1 passage
• The C3a/C3aR axis mediates anti-inflammatory activity and protects against uropathogenic E coli-induced kidney injury in mice.1 passage
• The C5a/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia/reperfusion injury.1 passage
• The Dietary Approaches to Stop Hypertension (DASH) diet in chronic kidney disease: should we embrace it?1 passage
• The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease.1 passage
• The IL-4 receptor α has a critical role in bone marrow-derived fibroblast activation and renal fibrosis.1 passage
• The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.1 passage
• The International Society of Nephrology (ISN) and the American Nephrologists of Indian Origin (ANIO) Online Clinical Nephropathology Certificate (CNC) program.1 passage
• The International Society of Nephrology's International Consortium of Collaborators on Chronic Kidney Disease of Unknown Etiology: report of the working group on approaches to population-level detection strategies and recommendations for a minimum dataset.1 passage
• The MEST score provides earlier risk prediction in lgA nephropathy.1 passage
• The Perceived Medical Condition Self-Management Scale can be applied to patients with chronic kidney disease.1 passage
• The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.1 passage
• The Rho-GTPase binding protein IQGAP2 is required for the glomerular filtration barrier.1 passage
• The SAM domain of ANKS6 has different interacting partners and mutations can induce different cystic phenotypes.1 passage
• The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine.1 passage
• The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury.1 passage
• The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.1 passage
• The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.1 passage
• The TNF-derived TIP peptide activates the epithelial sodium channel and ameliorates experimental nephrotoxic serum nephritis.1 passage
• The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus.1 passage
• The absorbing life of bile acids.1 passage
• The acute kidney injury to chronic kidney disease transition in a mouse model of acute cardiorenal syndrome emphasizes the role of inflammation.1 passage
• The age-calibrated measured glomerular filtration rate improves living kidney donation selection process.1 passage
• The ammonia transporter RhCG modulates urinary acidification by interacting with the vacuolar proton-ATPases in renal intercalated cells.1 passage
• The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.1 passage
• The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.1 passage
• The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation.1 passage
• The balance of the evidence on acid-base homeostasis and progression of chronic kidney disease.1 passage
• The battlefield at arteriovenous crossroads: invading arterial smooth muscle cells occupy the outflow tract of fistulas.1 passage
• The bias between different albumin assays may affect clinical decision-making.1 passage
• The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.1 passage
• The case of complement activation in COVID-19 multiorgan impact.1 passage
• The cell membrane repair protein MG53 modulates transcription factor NF-κB signaling to control kidney fibrosis.1 passage
• The changing epidemiology of acute kidney injury syndromes in the face of emerging respiratory viral pandemic illnesses.1 passage
• The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis.1 passage
• The choice of dialysate bicarbonate: do different concentrations make a difference?1 passage
• The circadian clock is disrupted in mice with adenine-induced tubulointerstitial nephropathy.1 passage
• The cleavage of gasdermin D by caspase-11 promotes tubular epithelial cell pyroptosis and urinary IL-18 excretion in acute kidney injury.1 passage
• The clinical significance of medial arterial calcification in end-stage renal disease in women.1 passage
• The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis.1 passage
• The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.1 passage
• The clinicopathologic spectrum of segmental membranous glomerulopathy.1 passage
• The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.1 passage
• The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins.1 passage
• The deacetylase sirtuin 6 protects against kidney fibrosis by epigenetically blocking β-catenin target gene expression.1 passage
• The decline in kidney function with chromium exposure is exacerbated with co-exposure to lead and cadmium.1 passage
• The definition of acute kidney injury and its use in practice.1 passage
• The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss.1 passage
• The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial.1 passage
• The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk.1 passage
• The elusive podocyte crossmatch for recurrent focal segmental glomerulosclerosis.1 passage
• The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond.1 passage
• The emerging role of complement inhibitors in transplantation.1 passage
• The epidemiology and prognostic factors of mortality in critically ill children with acute kidney injury in Taiwan.1 passage
• The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons.1 passage
• The fragility of significant results underscores the need of larger randomized controlled trials in nephrology.1 passage
• The function of the parathyroid oxyphil cells in uremia: still a mystery?1 passage
• The genetic and clinical spectrum of a large cohort of patients with distal renal tubular acidosis.1 passage
• The growth of AKI: half empty or half full, it's the size of the glass that matters.1 passage
• The growth of acute kidney injury: a rising tide or just closer attention to detail?1 passage
• The hallmarks of mitochondrial dysfunction in chronic kidney disease.1 passage
• The harmful effect of indoxyl sulfate on neovascularization in chronic kidney disease.1 passage
• The impact of cold ischemia time on renal transplant outcome.1 passage
• The impact of epilepsy and its treatment in patients with end-stage renal disease.1 passage
• The incidence of pediatric acute kidney injury is increased when identified by a change in a creatinine-based electronic alert.1 passage
• The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis.1 passage
• The inflammatory state is a risk factor for cardiovascular disease and graft fibrosis in kidney transplantation.1 passage
• The leukotriene B1 passage
• The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.1 passage
• The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.1 passage
• The lupus nephritis management renaissance.1 passage
• The lymphotoxin β receptor is a potential therapeutic target in renal inflammation.1 passage
• The meaning of borderline rejection in kidney transplantation.1 passage
• The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.1 passage
• The molecular mechanisms of hemodialysis vascular access failure.1 passage
• The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients.1 passage
• The mortality risk with graft function has decreased among children receiving a first kidney transplant in the United States.1 passage
• The motor protein Myo1c regulates transforming growth factor-β-signaling and fibrosis in podocytes.1 passage
• The net effect of ANCA on neutrophil extracellular trap formation.1 passage
• The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease.1 passage
• The overdriven glomerulus as a cardiovascular risk factor.1 passage
• The pathogenesis of human membranous nephropathy: we are (almost) there.1 passage
• The pattern recognition receptor, Mincle, is essential for maintaining the M1 macrophage phenotype in acute renal inflammation.1 passage
• The phenotypes of podocytes and parietal epithelial cells may overlap in diabetic nephropathy.1 passage
• The phosphoinositide 3-kinase inhibitor alpelisib restores actin organization and improves proximal tubule dysfunction in vitro and in a mouse model of Lowe syndrome and Dent disease.1 passage
• The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo.1 passage
• The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis.1 passage
• The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation.1 passage
• The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds.1 passage
• The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis.1 passage
• The promise of single-cell RNA sequencing for kidney disease investigation.1 passage
• The proteome microenvironment determines the protective effect of preconditioning in cisplatin-induced acute kidney injury.1 passage
• The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.1 passage
• The renal artery is involved in Chinese Takayasu's arteritis patients.1 passage
• The renal draining lymph nodes in acute inflammatory kidney disease.1 passage
• The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.1 passage
• The rise of FGF23: should insights from population-based studies inform future clinical trials?1 passage
• The risk of allograft failure and the survival benefit of kidney transplantation are complicated by delayed graft function.1 passage
• The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.1 passage
• The risk of chronic kidney disease and mortality are increased after community-acquired acute kidney injury.1 passage
• The risk of chronic kidney disease in a metabolically healthy obese population.1 passage
• The risk of hospitalization and modality failure with home dialysis.1 passage
• The role of PDGF-D in healthy and fibrotic kidneys.1 passage
• The role of cannabinoid signaling in acute and chronic kidney diseases.1 passage
• The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?1 passage
• The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.1 passage
• The role of urinary peptidomics in kidney disease research.1 passage
• The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.1 passage
• The scar that never felt a wound.1 passage
• The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.1 passage
• The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.1 passage
• The spatially resolved transcriptional profile of acute T cell-mediated rejection in a kidney allograft.1 passage
• The spectrum of kidney biopsy findings in HIV-infected patients in the modern era.1 passage
• The spectrum of kidney biopsy findings in patients with morbid obesity.1 passage
• The spleen as a bidirectional signal transducer in acute kidney injury.1 passage
• The sweetest thing: blocking fructose metabolism to prevent acute kidney injury?1 passage
• The third path of tubulointerstitial fibrosis: aberrant endothelial secretome.1 passage
• The time for next-generation molecular genetic diagnostics in nephrology is now!1 passage
• The time of onset of intradialytic hypotension during a hemodialysis session associates with clinical parameters and mortality.1 passage
• The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy.1 passage
• The transcriptomic signature of the aging podocyte.1 passage
• The uremic toxin oxythiamine causes functional thiamine deficiency in end-stage renal disease by inhibiting transketolase activity.1 passage
• The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action.1 passage
• The urinary proteome and metabonome differ from normal in adults with mitochondrial disease.1 passage
• The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.1 passage
• The vascular secret of Klotho.1 passage
• The weekend effect alters the procurement and discard rates of deceased donor kidneys in the United States.1 passage
• The weekend effect: transplantation is not "immune".1 passage
• The zinc fingers and homeoboxes 2 protein ZHX2 and its interacting proteins regulate upstream pathways in podocyte diseases.1 passage
• Therapeutic transformation for diabetic kidney disease.1 passage
• Therapy for kidney fibrosis: is the Src kinase a potential target?1 passage
• Three-dimensional architecture of nephrons in the normal and cystic kidney.1 passage
• Thrombomodulin ameliorates transforming growth factor-β1-mediated chronic kidney disease via the G-protein coupled receptor 15/Akt signal pathway.1 passage
• Thrombotic microangiopathy associated with monoclonal gammopathy.1 passage
• Time-dependent effect, immortal bias, and competing risk: 3 components that should be handled to assess the impact of covariates on occurrence of acute kidney injury.1 passage
• Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death.1 passage
• Timing is everything? Reconciling the results of recent trials in acute kidney injury.1 passage
• Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease.1 passage
• Tissue inhibitor metalloproteinase-2 (TIMP-2) • IGF-binding protein-7 (IGFBP7) levels are associated with adverse outcomes in patients in the intensive care unit with acute kidney injury.1 passage
• Total kidney volume: the most valuable predictor of autosomal dominant polycystic kidney disease progression.1 passage
• Toward individual glomerular phenotyping: advent of precision medicine in kidney biopsies.1 passage
• Toward quantitating the burden of glomerulonephritis in the United States.1 passage
• Towards an understanding of kidney diseases associated with WT1 mutations.1 passage
• Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation.1 passage
• Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis.1 passage
• Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression.1 passage
• Transcription factors that determine parathyroid development power PTH expression.1 passage
• Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.1 passage
• Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury.1 passage
• Transient antenatal Bartter's Syndrome and X-linked polyhydramnios: insights from the genetics of a rare condition.1 passage
• Transitional B cell subsets-a convincing predictive biomarker for allograft loss?1 passage
• Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be.1 passage
• Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis.1 passage
• Treatment of hyperkalemia: something old, something new.1 passage
• Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.1 passage
• Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly.1 passage
• Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.1 passage
• Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States.1 passage
• Tuberculosis and chronic kidney disease: an emerging global syndemic.1 passage
• Tubular proteinuria in patients with HNF1α mutations: HNF1α drives endocytosis in the proximal tubule.1 passage
• Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury.1 passage
• Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis.1 passage
• Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes.1 passage
• Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.1 passage
• Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway.1 passage
• Twenty years of evolving trends in racial disparities for adult kidney transplant recipients.1 passage
• U-shaped dietary sodium-associated incidence of chronic kidney disease cautions against salt overrestriction in hypertension.1 passage
• Ultrasound-based imaging methods of the kidney-recent developments.1 passage
• Uncontrolled DCD donation-tilting at windmills or pushing against an open door?1 passage
• Uncovering genetic mechanisms of kidney aging through transcriptomics, genomics, and epigenomics.1 passage
• Uncovering real mortality trends in ESRD patients.1 passage
• Uncovering the etiology of CINAC, a complex and mysterious renal syndrome: the invaluable role of histopathology and electron microscopy.1 passage
• Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.1 passage
• Understanding the immune signature fingerprint of peritoneal dialysis-related peritonitis.1 passage
• Understanding the kidney one cell at a time.1 passage
• Understanding the pathogenesis of vascular calcification: timing is everything.1 passage
• Unique chloride-sensing properties of WNK4 permit the distal nephron to modulate potassium homeostasis.1 passage
• Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients.1 passage
• Unique molecular changes in kidney allografts after simultaneous liver-kidney compared with solitary kidney transplantation.1 passage
• Unlocking the code: mining the urinary proteome after renal transplantation.1 passage
• Unraveling the mechanisms of obesity-induced hyperoxaluria.1 passage
• Unraveling the osteocyte in CKD-MBD post-renal transplantation.1 passage
• Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.1 passage
• Untangling immunotactoid glomerulopathy in the MGRS era.1 passage
• Untangling the complex relationship between dietary acid load and glucocorticoid metabolism.1 passage
• Update on endocarditis-associated glomerulonephritis.1 passage
• Update on renal blood oxygenation level-dependent MRI to assess intrarenal oxygenation in chronic kidney disease.1 passage
• Updating the International IgA Nephropathy Prediction Tool for use in children.1 passage
• Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis.1 passage
• Upregulation of HLA-F expression by BK polyomavirus infection induces immune recognition by KIR3DS1-positive natural killer cells.1 passage
• Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?1 passage
• Uremic encephalopathy.1 passage
• Uremic pruritus.1 passage
• Urinary Dickkopf-3 and kidney injury in patients with chronic pulmonary disease.1 passage
• Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury.1 passage
• Urinary ammonia and long-term outcomes in chronic kidney disease.1 passage
• Urinary biomarkers of tubular injury in chronic kidney disease.1 passage
• Urinary citrate: helpful to predict acid retention in CKD patients?1 passage
• Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis.1 passage
• Urinary metabolites along with common and rare genetic variations are associated with incident chronic kidney disease.1 passage
• Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes.1 passage
• Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice.1 passage
• Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults.1 passage
• Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression.1 passage
• Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis.1 passage
• Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC.1 passage
• Uromodulin, kidney function, cardiovascular disease, and mortality.1 passage
• Use of an ECG-based confirmatory technique for bedside placement of reverse-tunneled cuffed dialysis catheters in three morbidly obese patients.1 passage
• Use of extracorporeal treatments in the management of poisonings.1 passage
• Use of peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City: a multicenter observational study.1 passage
• Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation?1 passage
• Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.1 passage
• Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits.1 passage
• Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease.1 passage
• Vascular access of last resort.1 passage
• Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury.1 passage
• Vascular calcification in chronic kidney disease: different bricks in the wall?1 passage
• Vascular calcification in chronic kidney disease: here to stay?1 passage
• Vitamin D: can you have too much of a good thing in chronic kidney disease?1 passage
• Vitamin K and cardiovascular complications in chronic kidney disease patients.1 passage
• Vitamin K antagonism aggravates chronic kidney disease-induced neointimal hyperplasia and calcification in arterialized veins: role of vitamin K treatment?1 passage
• Von Willebrand factor regulates complement on endothelial cells.1 passage
• We still go for the jugular: implications of the 3SITES central venous catheter study for nephrology.1 passage
• What can copeptin tell us in patients with autosomal dominant polycystic disease?1 passage
• What is myeloperoxidase doing in ANCA-associated glomerulonephritis?1 passage
• What is nephrocalcinosis?1 passage
• When there will never be a randomized controlled trial.1 passage
• Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis.1 passage
• Whole exome sequencing identified ATP6V1C2 as a novel candidate gene for recessive distal renal tubular acidosis.1 passage
• Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity.1 passage
• Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?1 passage
• Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?1 passage
• Wnt/β-catenin links oxidative stress to podocyte injury and proteinuria.1 passage
• Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome.1 passage
• Worldwide growing epidemic of CKD: fact or fiction?1 passage
• Would hemodialysis patients benefit from a Staphylococcus aureus vaccine?1 passage
• Would prescribing target Kt dose adjusted for body surface area improve hemodialysis outcomes?1 passage
• YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology.1 passage
• Your blood pressure might be normal, but what about your podocytes?1 passage
• Youthful systemic milieu alleviates renal ischemia-reperfusion injury in elderly mice.1 passage
• ZAG-a novel biomarker for cardiovascular risk in ESRD patients?1 passage
• Zero health care-associated respiratory viral infections: impact of enhanced infection prevention on a renal unit during the coronavirus disease 2019 pandemic.1 passage
• eGFR conundrum: is this the "truth" or simply another "label"?1 passage
• mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.1 passage
• p-Cresyl sulfate is associated with carotid arteriosclerosis in hemodialysis patients and promotes atherogenesis in apoE-/- mice.1 passage
• p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky.1 passage
• α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.1 passage
• β1 passage
• β-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects.1 passage
• β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells.1 passage
• β3-Adrenoreceptors in the thick ascending limb of Henle and in principal cells of the collecting duct work to concentrate urine.1 passage
• γδ T-cell function is inhibited in end-stage renal disease and impacted by latent tuberculosis infection.1 passage